MXPA04011560A - Formulacion anti-cancer. - Google Patents
Formulacion anti-cancer.Info
- Publication number
- MXPA04011560A MXPA04011560A MXPA04011560A MXPA04011560A MXPA04011560A MX PA04011560 A MXPA04011560 A MX PA04011560A MX PA04011560 A MXPA04011560 A MX PA04011560A MX PA04011560 A MXPA04011560 A MX PA04011560A MX PA04011560 A MXPA04011560 A MX PA04011560A
- Authority
- MX
- Mexico
- Prior art keywords
- rubidium
- ursolate
- ursolic acid
- composition
- mmp
- Prior art date
Links
- 239000002842 anticancer formulation Substances 0.000 title description 2
- 239000000203 mixture Substances 0.000 claims abstract description 10
- 229910052701 rubidium Inorganic materials 0.000 claims abstract description 10
- IGLNJRXAVVLDKE-UHFFFAOYSA-N rubidium atom Chemical compound [Rb] IGLNJRXAVVLDKE-UHFFFAOYSA-N 0.000 claims abstract description 10
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 claims abstract description 7
- 229940096998 ursolic acid Drugs 0.000 claims abstract description 7
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 claims abstract description 7
- 206010027476 Metastases Diseases 0.000 claims abstract description 5
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 5
- 201000011510 cancer Diseases 0.000 claims abstract description 5
- 230000009401 metastasis Effects 0.000 claims abstract description 5
- WCGUUGGRBIKTOS-GPOJBZKASA-M (1s,2r,4as,6ar,6as,6br,8ar,10s,12ar,14bs)-10-hydroxy-1,2,6a,6b,9,9,12a-heptamethyl-2,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydro-1h-picene-4a-carboxylate Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C([O-])=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-M 0.000 claims abstract 6
- 102100026802 72 kDa type IV collagenase Human genes 0.000 claims description 3
- 101710151806 72 kDa type IV collagenase Proteins 0.000 claims description 3
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 claims description 3
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 claims description 3
- 108010010803 Gelatin Proteins 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 229940124761 MMP inhibitor Drugs 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- 241000208832 Viburnum Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001740 anti-invasion Effects 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Steroid Compounds (AREA)
Abstract
Composicion para detener la metastasis de celulas de cancer que comprende rubidio ursolato. El rubidio ursolato se forma de una mezcla de rubidio y acido ursolico obtenido de la corteza de la planta Virburnum.
Description
FORMULACION ANTI-CANCER
Esta invención se relaciona a formulaciones para la prevención o para detener la metástasis de células de cáncer.
DESCRIPCION DE LA INVENCION
El ácido ursólico derivado de la corteza de la planta Viburnum ha sido reportado que tiene actividad antiinvasiva con células de fibrosarcoma humanas. El mecanismo de actividad fue reportado para ser ideado en envolver la regulación a la baja de MMP-9, una metaloprotexnasa de matriz que degrada gelatina. Ha sido además reportado que no hubo efecto sobre MMP-2, la segunda de dos MMP's que degradan gelatina.
De acuerdo con la presente invención, el Rubidio es combinado con ácido ursólico para hacer una sal del ácido, Rubidio Ursolato, que cuando se administra a un paciente, regula a la baja MMP-2 y MMP-9. Esta combinación de los dos inhibidores de MMP proporciona un tratamiento para de-tener el esparcimiento o metástasis de las células de cáncer, en general .
Claims (7)
1. Una composición para detener la metástasis de células de cáncer que comprende cantidades farmacéuticamente eficaces de rubidio ursolato.
2. La composición de conformidad con la reivindicación 1, en donde la composición, cuando se administra a un paciente, regula a la baja el MMP-2 y MMP-9.
3. La composición de conformidad con la reivindicación 1, en donde el rubidio ursolato se forma de una mezcla de rubidio y ácido ursólico.
4. La composición de conformidad con la reivindicación 3, en donde el ácido ursólico se obtiene -de la corteza de la planta Virburnum.
5. Un método para detener la metástasis de células de cáncer que comprende administrar a un paciente en necesidad de la misma, una cantidad farmacéuticamente eficaz de rubidio ursolato.
6. El método de conformidad con la reivindicación 5, en donde el rubidio ursolato se forma de una mezcla de ácido ursólico y rubidio.
7. El método de conformidad con la reivindicación 5, en donde el ácido ursólico se deriva de la corteza de la planta Virburnum.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38246002P | 2002-05-24 | 2002-05-24 | |
| PCT/US2003/016188 WO2003099218A2 (en) | 2002-05-24 | 2003-05-22 | Anti-cancer formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA04011560A true MXPA04011560A (es) | 2005-06-08 |
Family
ID=29584412
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA04011560A MXPA04011560A (es) | 2002-05-24 | 2003-05-22 | Formulacion anti-cancer. |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20040023937A1 (es) |
| EP (1) | EP1507542A4 (es) |
| JP (1) | JP2005527613A (es) |
| AU (1) | AU2003248555A1 (es) |
| CA (1) | CA2486704A1 (es) |
| MX (1) | MXPA04011560A (es) |
| WO (1) | WO2003099218A2 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005020909A2 (en) * | 2003-08-25 | 2005-03-10 | Greystone Medical Group, Inc. | Cellular depolarization and regulation of matrix metalloproteinases |
| MX2010006300A (es) * | 2007-12-11 | 2011-08-17 | Stephen H Monroe | Composicion de solucion acuosa reguladora para el tratamiento del ambiente celular y canales ionicos y metodos para uso de la misma. |
| DE102009012561B4 (de) * | 2009-03-11 | 2015-01-22 | Rohde & Schwarz Gmbh & Co. Kg | Verfahren und Mobilfunktester zur Erzeugung einer global gültigen Adresse für ein Mobilfunkgerät für eine Mobilfunk-Testprozedur |
| CN103923159B (zh) * | 2014-04-24 | 2016-04-27 | 长沙麓园生物科技有限公司 | 一种从枇杷叶中提取精制熊果酸的方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994011010A2 (en) * | 1992-11-06 | 1994-05-26 | H.E. Stanley Pharmaceuticals, Inc. | Compositions of oak bark extract, related synthetic compositions, and method of using same |
| JP3041232B2 (ja) * | 1995-11-16 | 2000-05-15 | 日本ケミカルリサーチ株式会社 | 癌転移抑制剤 |
| US5932617A (en) * | 1998-02-06 | 1999-08-03 | Woundfast Pharmaceuticals Inc. | Wound-treating composition and method |
| CN1371291A (zh) * | 1999-08-31 | 2002-09-25 | 布赖恩·C·贾尔斯 | 用于缓解肿瘤和抑制癌症的方法和制剂 |
| CA2418117A1 (en) * | 2000-07-31 | 2003-01-30 | The Nisshin Oillio, Ltd. | Antitumor agent |
| EP1461024A4 (en) * | 2001-11-29 | 2009-03-25 | Greystone Medical Group Inc | TREATMENT OF WOUNDS AND COMPOSITIONS USED |
-
2003
- 2003-05-22 US US10/443,476 patent/US20040023937A1/en not_active Abandoned
- 2003-05-22 WO PCT/US2003/016188 patent/WO2003099218A2/en active Application Filing
- 2003-05-22 AU AU2003248555A patent/AU2003248555A1/en not_active Abandoned
- 2003-05-22 MX MXPA04011560A patent/MXPA04011560A/es not_active Application Discontinuation
- 2003-05-22 CA CA002486704A patent/CA2486704A1/en not_active Abandoned
- 2003-05-22 EP EP03755441A patent/EP1507542A4/en not_active Withdrawn
- 2003-05-22 JP JP2004506745A patent/JP2005527613A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2003099218A2 (en) | 2003-12-04 |
| CA2486704A1 (en) | 2003-12-04 |
| WO2003099218A3 (en) | 2004-04-08 |
| AU2003248555A1 (en) | 2003-12-12 |
| EP1507542A4 (en) | 2008-01-23 |
| JP2005527613A (ja) | 2005-09-15 |
| US20040023937A1 (en) | 2004-02-05 |
| EP1507542A2 (en) | 2005-02-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Tradati et al. | Successful topical treatment of oral lichen planus and leukoplakias with fenretinide (4-HPR) | |
| BRPI0414876A (pt) | compostos e composições farmcêuticas para prevenção de overdose ou abuso e respectivos usos | |
| WO2007062093A3 (en) | Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor | |
| CA2484514A1 (en) | Compositions and methods for the prophylaxis and treatment of aphthous ulcers and herpes simplex lesions | |
| SG157406A1 (en) | Oral medicament for the modified release of at least one active principle, in multi-microcapsule form | |
| WO2004045593A3 (en) | Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy | |
| MY124648A (en) | Inhibitor of factor xa alone or in combination with an anti-platelet aggregation agent, for combating arterial thrombosis. | |
| BRPI0414500A (pt) | formulação farmacêutica composição para tratar uma infecção vaginal, e, métodos para tratar uma infecção vaginal, para estabilizar uma formulação de clindamicina, para tratar ou prevenir uma recorrência de uma infecção vaginal em uma paciente e para tratar condições vaginais | |
| WO2001030802A3 (en) | Therapeutic treatments comprising administration of certain steroids for blood cell deficiencies | |
| JP2018537503A (ja) | 末梢神経障害を治療するための方法及び組成物 | |
| WO2004039325A3 (en) | Treatment of pain with jnk inhibitors | |
| IS6558A (is) | Blandaðar sjúkdómsmeðferðir með æðaskaðandi virkni | |
| JP2006516571A5 (es) | ||
| BR0310061A (pt) | Métodos para o tratamento de doenças e condições respiratórias com um inibidor seletivo da inos e um inibidor da pde e suas composições | |
| AR026257A1 (es) | N-guanidinoalquilamidas, su preparacion, su uso y composiciones farmaceuticas que las contienen | |
| BR0201974A (pt) | Composição farmacêutica para tratamento de alterações do sono | |
| CA2494473A1 (en) | Stabilized protein compositions for topical administration and methods of making same | |
| MXPA04011560A (es) | Formulacion anti-cancer. | |
| JP2003503453A5 (ja) | ガバペンチンおよびプレガバリンを含む相乗作用組成物 | |
| Satapathy et al. | Topical-Ozonized Olive Oil–A Boon for Post-Extraction Cases: A Randomized Controlled Trial | |
| EP1550443A4 (en) | COMPOSITION AGAINST STRESS-BASED DISEASES | |
| US20020071814A1 (en) | Inhibition of ceramide for the prevention and treatment of oral mucositis induced by antineoplastic drugs or radiation | |
| WO2004033484A3 (en) | Use of stable glutamine derivatives to improve drug absorption | |
| WO2003043632A3 (en) | Use of bisindolmaleimide and gemcitabine for the treatment of cancer | |
| CA2499620A1 (en) | External preparation containing acetylsalicylic acid for inhibiting keloid formation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |